Clinical trials: Antipsychotic
Schizophrenia
Efficacy and Safety of Iloperidone Compared With Placebo and Active Control in Subjects With Acute Schizophrenia
The purpose of this study is to determine the safety and efficacy of iloperidone compared to placebo and an active comparator in the treatment of patients with schizophrenia in acute exacerbation.
- Trial name
- NCT00254202
- Testing
- Iloperidone, Ziprasidone
- Where
- 42 sites in United States, India
- Volunteers
- 593 people
- Sponsor
- Vanda Pharmaceuticals
Schizophrenia, Major Depressive Disorder
PHARMO Institute Seroquel Safety Study
The purpose of this observational study is to study specific outcomes of interest in users of quetiapine compared with all other atypical antipsychotics and specifically olanzapine and risperidone.
- Conditions
- Schizophrenia, Major Depressive Disorder, Bipolar Disorder, Generalized Anxiety Disorder
- Trial name
- PHARMO II (NCT01342120)
- Volunteers
- 18,325 people
- Sponsor
- AstraZeneca
Delirium
Prophylactic Olanzapine Versus Placebo for Prevention of Postoperative Delirium After Joint Replacement Surgery
In this study we wanted to determine if perioperative administration of olanzapine prior to knee or hip replacement surgery in high risk patients would prevent the onset of postoperative delirium.
- Trial name
- NCT00699946
- Testing
- olanzapine
- Where
- United States
- Volunteers
- 495 people, healthy volunteers welcome
- Sponsor
- The New England Baptist Hospital
Schizophrenia, Metabolic Syndrome
The Influence of Vitamin D on Atypical Antipsychotic-induced Weight Gain
Schizophrenia and bipolar disorders are major public health problems. The second generation anti-psychotic drugs have efficacy for both positive and negative symptoms and a favorable risk profile as far as movement disorders.
- Conditions
- Schizophrenia, Metabolic Syndrome, Vitamin D Deficiency
- Trial name
- NCT02281162
- Testing
- Blood Draw
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Creighton University
Schizophrenia
A Study of the Long-term Safety and Tolerability and the Long-term Effectiveness of Extended-release Oral Paliperidone in Patients Diagnosed With Schizophrenia
The purpose of this study is to evaluate the long-term safety and tolerability and the maintenance of effectiveness of a slow, extended-release oral formulation of paliperidone administered once daily to patients diagnosed with…
- Trial name
- NCT00210769
- Testing
- paliperidone ER Oros
- Volunteers
- 203 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia, Schizoaffective Disorders
Effects of Pravastatin on Cholesterol, Inflammation and Cognition in Schizophrenia
This study involves people with schizophrenia or schizoaffective disorder, who are currently taking antipsychotic medications. Some antipsychotic medications may cause an increase in cholesterol levels, which may lead to…
- Conditions
- Schizophrenia, Schizoaffective Disorders, Schizophreniform Disorders
- Trial name
- NCT01082588
- Testing
- Pravastatin
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Massachusetts General Hospital
Weight Gain
Lorcaserin for Weight Loss Management in Patients on Antipsychotics: A Pilot Study
The purpose of this study is to determine whether lorcaserin is effective for weight reduction in patients with weight gain as a result of antipsychotic medications.
- Trial name
- NCT01962402
- Testing
- lorcaserin, Intensive dietary counseling
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Southern California Institute for Research and Education
Anxiety Disorders
Study Comparing Risperidone vs Placebo as add-on Therapy in Patients With Generalized Anxiety Disorder Who Are Sub-optimally Responding to Standard Therapy.
The purpose of this trial is to determine the effectiveness of risperidone as an adjunctive treatment in patients with GAD who demonstrate a less-than-optimal response to their current anxiolytic treatment.
- Trial name
- NCT00086112
- Testing
- risperidone oral tablets
- Volunteers
- 301 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Bipolar Disorder (BD)
Body Weight Changes After Switching to Lurasidone for Antipsychotic-induced Weight Gain in Bipolar Disorder
Study Objective: To evaluate the treatment effectiveness and safety by analyzing prescription patterns in a routine clinical practice setting and observing changes in clinical indicators (weight, BMI, HAM-D, CGI-S, CGI-I) among…
- Trial name
- NCT07834112
- Testing
- Lurasidone
- Where
- South Korea
- Volunteers
- 155 people
- Sponsor
- Dong-Wook Kim
Schizophrenia
Randomized, Double-blinded, Placebo-controlled, Evaluating the Treatment With LB-102 in Patients With Acute Schizophrenia
This is a Phase 2, randomized, double-blind, placebo-controlled, multi-center inpatient study to evaluate the efficacy and safety of LB-102 in adult patients diagnosed with acutely exacerbated schizophrenia.
- Trial name
- NCT06179108
- Testing
- LB-102
- Where
- 25 sites in United States
- Volunteers
- 359 people
- Sponsor
- LB Pharmaceuticals Inc.
Overweight, Hyperlipidemia
The Effect of Switching to Aripiprazole on Heart Health in Overweight and Obese Patients With Schizophrenia
This is a 2-year study proposing to examine the effects of aripiprazole on heart health factors such as serum lipids, serum leptin, fasting blood sugar, body weight and blood pressure.
- Conditions
- Overweight, Hyperlipidemia, Cardiovascular Diseases
- Trial name
- NCT00222833
- Testing
- Aripiprazole
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Pittsburgh
Autism, Neuroleptic Treatment
Use of Pharmacogenetics in the Treatment of Children With Autistic Spectrum Disorders
Children with autism are often treated with psychiatric drugs. These medications have been shown to improve their language and social function, and are important in improving their quality of life.
- Trial name
- NCT00859664
- Testing
- Genotyping of Cytochrome P450
- Where
- Israel
- Volunteers
- 500 people
- Sponsor
- Assaf-Harofeh Medical Center
Schizophrenia
Oxcarbazepine as an Adjunct of Antipsychotic Therapy in Acute Schizophrenia
Over recent years an approach with the adjunctive administration of various anticonvulsant drugs has been discussed and a limited number of open and controlled studies were performed for carbamazepine, valproic acid, and…
- Trial name
- OXC-SCZ (NCT00637234)
- Testing
- Oxcarbazepine
- Where
- 2 sites in Germany
- Volunteers
- 54 people
- Sponsor
- University of Cologne
Schizophrenia
FYS Study: Epidemiological, Multicentre, Cross-sectional Study in a Clinical Practice Environment, About the Relationship Between Functioning Status and the Quality of Sleep Perceived by Schizophrenic Outpatients in Spain
The purpose of this study is to establish the relationship between performance of patients with schizophrenia and relationship with perceived quality of sleep.
- Trial name
- NCT01376492
- Testing
- Functioning assessment, Quality of sleep assessment
- Volunteers
- 709 people
- Sponsor
- Janssen-Cilag, S.A.
Psychotic Disorders
Reducing Weight Gain and Improving Metabolic Function in Children Being Treated With Antipsychotics
This study will test the effectiveness of two different treatments for children and adolescents who have gained weight on their antipsychotic medications.
- Trial name
- IMPACT (NCT00806234)
- Testing
- Aripiprazole or Perphenazine, Metformin, Olanzapine, quetiapine, risperidone, ziprasidone, aripiprazole, asenapine, iloperidone, lurasidone, paliperidone, or olanzapine/fluoxetine
- Where
- 4 sites in United States
- Volunteers
- 127 people
- Sponsor
- Johns Hopkins University
MDD
Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Active Adults, 18 to 35 Years Old, With Major Depressive Disorder Who Are in a School or Work Environment
To investigate the efficacy and safety of flexibly dosed adjunctive brexpiprazole treatment in active adults with MDD, 18 to 35 years old, who are experiencing an inadequate selective serotonin reuptake inhibitor (SSRI)/serotonin…
- Trial name
- NCT02013609
- Testing
- Brexpiprazole
- Where
- 24 sites in United States
- Volunteers
- 48 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
A Study Evaluating the Treatment Selection and Outcome When Changing Antipsychotic Treatment in Schizophrenic Patients
The purpose of the study is to evaluate the outcome of treatment switch defined as an improvement in CGI-CB scale (Clinical Global Impression - Clinical Benefit).
- Trial name
- ETOS (NCT00999895)
- Where
- 43 sites in Greece
- Volunteers
- 574 people
- Sponsor
- AstraZeneca
NSCLC Adenocarcinoma, Solid Tumor
Atamparib in Patients With Advanced Solid Tumors
This is a multi-part, open-label, non-randomized phase Ib/II clinical trial designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of atamparib, an investigational agent, in patients…
- Trial name
- PARP7 (NCT07374419)
- Testing
- atamparib escalation levels, atamparib RP2D
- Where
- China
- Volunteers
- 178 people
- Sponsor
- Nerviano Medical Sciences (Shanghai) Ltd.
Psychosis
Niapsan as Add -on Therapy to Antipsychotic Treatment in First Episode Psychosis
The purpose of this study is to help understand if by adding Niaspan FCT (study drug) to antipsychotic medications will it help maintain or improve cognitve functioning.
- Trial name
- NCT01720095
- Testing
- Niaspan
- Where
- Canada
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Nova Scotia Health Authority
Schizophrenia, Schizophreniform Disorder
Omega-3 Dietary Supplements in Schizophrenia
This 16-week placebo-control study looks to investigate whether patients with schizophrenia for two years or less may benefit from omega-3 supplements.
- Conditions
- Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, Bipolar Disorder
- Trial name
- NCT01786239
- Testing
- Risperidone, Omega-3 capsules
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Delbert Robinson